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Improving the clinical significance of medical researchIn the classic Hippocratic tradition, diagnosis, prognosis,
and treatment are inherently connected around just one tar-
get: to improve the patient’s health [1]. And although scien-
tific progress sometimes requires that researchers especially
focus on one of the elements of this triad, they should al-
ways collaborate to integrate their work in guidelines and
practices to serve that key target. This should make inves-
tigators alert to use any opportunity to anticipate this con-
nection in their research. This sounds self-evident, but
there are too many examples of highly sophisticated treat-
ments being developed without appropriate protocol to pre-
select the appropriate patient subgroups, and e probably
even more e of advanced diagnostic technologies yielding
detailed biomedical information without clear perspectives
for better treatment [2]. As to the latter, the work by Siontis
et al. is very important. In a systematic review of a large
number of randomized controlled trials evaluating diagnos-
tic interventions, they found that in only one in five there
was evidence of significant changes in patient outcomes.
Moreover, the effect of testing on patient outcomes was
not correlated with further interventions, nor with diagnos-
tic accuracy of tests. The authors recommend that diagnos-
tic test evaluation should routinely include effects on
various outcomes and that its reporting should be more pa-
tient-centered.
The clinical significance of randomized trials may also
be less robust than reporting of statistically significant re-
sults suggest, unless the number of events is also taken into
account, as is shown by Walsh and his group. In a review of
RCTs reporting such results in high-impact medical jour-
nals, they analyzed how many events made the difference
between a significant and non-significant result, using their
newly developed ‘Fragility Index.’ As it was shown that in
many RCTs significant results hinge on small numbers of
events, the authors conclude that the Fragility Index com-
plements the P-value and helps identify less robust results.
The importance of paying attention to robustness of evi-
dence is underlined by Alexander c.s., who reviewed a sam-
ple of the World Health Organization guidelines that had
been rated according to the GRADE approach. The authors
found that strong recommendations based on low or very
low confidence estimates are very frequently made in
WHO guidelines, and emphasize the need for further study
on the reasons for such high uncertainty recommendations.
Considering appropriate presentation of evidence,
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prevention of cardiovascular events, Schmidt and his team
studied the reporting and justification of exclusion criteria,
and the extent to which exclusion criteria affected general-
izability of study results. Virtually all trials reported the ap-
plied exclusion criteria, but only one of the 113 articles
justified them. While there were no indications that gener-
alizability was affected, the authors recommend better re-
porting of the reasons for using exclusion criteria. Also,
inclusion of studies in systematic reviews is not always ap-
propriately justified. For example, Ijaz and colleagues dem-
onstrate in a review of all Cochrane reviews that considered
nonrandomized studies that most did not justify including
such studies. And when they do, most are not in line with
Cochrane recommendations, while risk of bias assessment
varies to a great extent. The authors provide recommenda-
tions for improvement.
Like criteria for inclusion and exclusion, blinding in
randomized trials is often blindly used. Mathieu and co-
authorsrevisited the justification of this principle in a theo-
retical analysis of the potential for bias in randomized trials
even after successful blinding. They conclude that in order
to fully eliminate bias, a state of complete ambivalence
about allocation of every trial participant should be estab-
lished. However, this may be difficult to achieve and may
reduce generalizability of the trial’s findings.
Because problems with internal and external validity can
never be excluded, in the discussion sections of research
papers authors should always consider known and potential
limitations of their work. In connection to work by Ioanni-
dis [3], Yazici c.s., having the impression that in doing so
basic science articles might perform less well than clinical
research reports, compared the discussion sections of these
two types of papers published in leading rheumatology
journals. They found, indeed, a striking difference, and
therefore make recommendations to promote self-critique,
especially in basic science articles.
As to appropriate reporting, the abstracts of research pa-
pers also deserve attention. For the field of oncology this
was evaluated by Ghimire and co-workers in a systematic
review of phase III trials, using a score based on the CON-
SORT for Abstract guidelines and comparing the pre- and
post-CONSORT periods. The investigators conclude that
the reporting quality of RCT abstracts showed suboptimal
improvement over time and that stricter adherence to the
guidelines is needed.
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ported by graphical tools to a great extent. Tan et al. show
this for reporting network meta-analysis (NMA), with the
aim of increasing accessibility, transparency, interpretabil-
ity, and acceptability of such analyses. Using recommenda-
tions by agencies such as the National Institute for Health
and Care Excellence, novel graphical approaches were de-
signed. These tools can be tailored to display results rele-
vant to the research question of interest, and targeted at a
whole spectrum of users, from analysts to clinicians.
Patient-reported outcome measurement instruments have
been recognized for decades now as key endpoints in clin-
ical research [4]. In contrast to most other instruments, the
Patient-Specific Functional Scale (PSFS) does not start
from a preset generic or specific health-related content,
but from preferences and priorities of individual patients.
Based on data from a large series of consecutive physical
therapy patients, Haxby Abbott c.s. examined the validity
of the PSFS, and concluded that it is an appropriate meas-
ure for statistical comparisons in clinical research. In eval-
uating patient reported outcome measurement instruments,
insight in the minimal clinically important improvement
(MCII) is essential. Ward and his team add to this insight,
by examining baseline dependence of MCIIs for three
measures for rheumatoid arthritis (RA) activity. They con-
clude that variation in MCII by baseline values is attribut-
able to floor and ceiling effects rather than to
expectations of particular patients. Minimally important
change was also evaluated for the Manchester-Oxford Foot
Questionnaire (MOXFQ). For this purpose, Dawson et al.
used data from a prospective before-after study of patients
undergoing foot or ankle surgery. Their findings can assist
the interpretation of MOXFQ outcomes and can help re-
searchers in this field to more precisely plan future studies.
Johnson and co-workers developed and evaluated the
sensibility of a SSc (systemic sclerosis) specific instrument
for use in a forced-choice study, conducted a forced-choice
study to reduce and weight the criteria for SSc, and ex-
plored the agreement among experts on which patients
are considered to have SSc. Following this approach, they
defined a system that successfully reduced the number of
candidate criteria, and produced a measure of the relative
probability that a particular case has SSc. As the authorssuggest, their work may serve as a template for develop-
ment of classification criteria for other diseases.
In dealing with non-response in clinical epidemiological
studies, safeguarding external validity by avoiding selective
recruitment is one of the main objectives. In this context,
David c.s. evaluated substitution sampling as an alternative
for more usual recruitment strategies such as sending re-
minders, using data from a prospective cohort study among
diabetes patients. Their findings support substitution sam-
pling as a recruitment option, as concerns about a higher
risk of bias seem unwarranted. Santin and collaborators
studied whether reweighting can correct for unit non-
response in an occupational health surveillance survey, by
linking survey data to administrative databases and socio-
demographic data. The authors conclude that this approach
can indeed effectively correct for nonresponse bias, while
using sociodemographic data solely may not be sufficient
for this purpose. As not only response at baseline but also
continued retention in a study is of utmost importance, also
from the perspective or efficient use of time and resources,
the letter by Bennett Johns on and her group is very inter-
esting. In a multinational study on possible environmental
triggers of type I diabetes in children (the TEDDY Study),
they developed a cumulative risk model to identify families
most likely to leave the study within one year. Their ap-
proach may be used to focusing efforts to keep participants
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